Company Description

Gyre Therapeutics, formerly Catalyst Bio, is a biopharmaceutical company primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis ('MASH fibrosis'), formerly known as Nonalcoholic Steatohepatitis (NASH) in the U.S.